Research FOR Patients
-For an informed and empowered opinion-
All the trials listed on our site have been properly vetted for scientific accuracy. Many thanks to Dr Simone Green – Hull and East Yorkshire Hospitals NHS Trust - for the continuous work in updating the listing.
MONOCLE IS NOW CLOSED TO RECRUITMENT
The trial was unable to demonstrate that Tefinostat had any effect in modifying CMML
- SUBTYPE OF MDS: Chronic myelomonocytc leukaemia (CMML)
- SEVERITY OF MDS: CMML specific prognostic score (CPSS) Intermediate-2 or high risk
- NAME OF DRUG: Tefinostat, a histone deacetylase inhibitor that targets monocytes. Tefinostat will be administered orally on a continuous basis for at least 6 cycles each 28 days in length.